tbuckley/cabot-search huggingface dataset:
Systemic and Radiation Therapy Approaches for Locally Advanced Non–Small-Cell Lung Cancer
Authors: Kristin A. Higgins, Sonam Puri, Jhanelle E. Gray
Journal: Journal of Clinical Oncology (2022)

The treatment for locally advanced non-small-cell lung cancer has changed dramatically over the past several years, with consolidative immunotherapy after concurrent chemoradiation becoming the new standard of care. Five-year survival outcomes have substantially improved with this approach. Despite these advances, further improvements are needed as the majority of patients ultimately develop progression of disease. The next-generation immunotherapy trials are currently being conducted that include approaches such as concurrent immunotherapy and addition of other therapeutic agents in the concurrent and consolidative settings. Specific unmet needs continue to exist for patients who develop disease progression after concurrent chemoradiation and immunotherapy, as well as defining the best treatment for patients with driver mutations. Future directions also include refinement of radiation techniques to reduce toxicities as much as possible, as well as the use of circulating tumor DNA in the surveillance setting. The current scientific landscape shows promising approaches that may further improve outcomes for patients with locally advanced non-small-cell lung cancer.
TCT-301 Lesion-specific myocardial mass: A new index for diagnosis and treatment of coronary artery disease
Authors: Jin-Ho Choi, Hyung Yoon Kim, Hong Seok Lim, Joon Hyung Doh, Chang-Wook Nam, Bon-Kwon Koo, Jin-Ho Choi
Journal: Journal of the American College of Cardiology (2015)
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
Authors: Aaron C. Tan, Daniel S.W. Tan
Journal: Journal of Clinical Oncology (2022)

Lung cancer has traditionally been classified by histology. However, a greater understanding of disease biology and the identification of oncogenic driver alterations has dramatically altered the therapeutic landscape. Consequently, the new classification paradigm of non-small-cell lung cancer is further characterized by molecularly defined subsets actionable with targeted therapies and the treatment landscape is becoming increasingly complex. This review encompasses the current standards of care for targeted therapies in lung cancer with driver molecular alterations. Targeted therapies for EGFR exon 19 deletion and L858R mutations, and ALK and ROS1 rearrangements are well established. However, there is an expanding list of approved targeted therapies including for BRAF V600E, EGFR exon 20 insertion, and KRAS G12C mutations, MET exon 14 alterations, and NTRK and RET rearrangements. In addition, there are numerous other oncogenic drivers, such as HER2 exon 20 insertion mutations, for which there are emerging efficacy data for targeted therapies. The importance of diagnostic molecular testing, intracranial efficacy of novel therapies, the optimal sequencing of therapies, role for targeted therapies in early-stage disease, and future directions for precision oncology approaches to understand tumor evolution and therapeutic resistance are also discussed.
Error in Key Points
Journal: JAMA Network Open (2021)

Shabbir M. H. Alibhai, MD, MSc; Henriette Breunis, CCRP; Gregory Feng, HBSc; Narhari Timilshina, MPH; Aaron Hansen, MBBS; Padraig Warde, MBChB; Richard Gregg, MD; Anthony Joshua, MBBS, PhD; Neil Fleshner, MD, MPH; George Tomlinson, PhD; Urban Emmenegger, MD
The effect of a passive coronary sinus defibrillation lead on the ventricular defibrillation threshold Michael E. Benser, Steven D. Girouard, Chery R. Killingsworth, Gregory P. Walcott, Raymond E. Ideker. Guidant Corp., St. Paul, MN, University of Alabama at Birmingham, Birmingham, AL
Journal: Journal of the American College of Cardiology (2001)
Lectures on Pharmacy and the British Pharmacop ia: Delivered before the Society of Apothecaries of London, November 28th, 1899
Authors: N. Tirard
Journal: BMJ (1899)

On the last occasion I spoke of the Pharmacopacia mainly as it concerned the medical student.I then briefly mentioned the lengthy list of omissions, to which I drew your attention with considerable satisfaction.The needs of the medical student are not far removed from those of the medical man, who, like the student, desires accuracy, simplification, and the elimination of useless material.He is also interested in the additions and altera- tions that may be made.These changes are determined by the scope and limitations of the British Pharmacopesia, and it is convenient to consider these together.Although lately one member of the Pharmacopceia Commit- tee in a friendly way criticised, the suggestion in the syllabus that there could possibly be any limitations in connection with the Pharmacopcesa, nevertheless the limitations and scope are accurately defined in the preface.The Therapeutic Committee of the British Medical Association endeavoured to ascertain the views of medical men with regard to many drugs that might possibly be omitted, or at all events with regard to a list that was drawn up, and in which medical men were asked to indi- cate the relative frequency of their employment of certain drugs.The information thus obtained was published in the BRITISH MEDICAL JOURNAL and presented to the Pharmacopoeia Committee of the General Medical Council.This summary appeared to afford a measure of the requirements of medical men, but it was not quite satisfactory, since of the number that had been sent out, nearly 12,5CO, only about half were returned.Some surprise was felt when it was found that although we had drawn up a list of about 120 drugs or preparations, thinking that many were never used at all, yet every single drug in that list appeared to be used often by some medical men.For instance, copper nitrate was often used by 22, matico leaves by 67, cetraria was often used by 44, decoc- tion of cetraria was often used by 52.Such results were not
Randomized phase II selection study of ramucirumab and paclitaxel versus FOLFIRI in refractory small bowel adenocarcinoma: SWOG S1922.
Authors: Michael J. Overman, Katherine A Guthrie, Mohamed E. Salem, Katrina Sophia Pedersen, Aparna Kalyan, Shay Bellasea, Philip Agop Philip
Journal: Journal of Clinical Oncology (2022)

TPS643 Background: Small bowel adenocarcinoma is a rare malignancy with limited data to support the choice of systemic chemotherapy beyond the frontline setting. Though second-line therapy has historically been extrapolated from colorectal cancers, recent molecular data has demonstrated small bowel adenocarcinoma to be genomically unique when compared to either colon or gastric cancer. Retrospective analyses of irinotecan- and taxane-based therapies and one prospective phase II clinical trial of nab-paclitaxel have demonstrated likely activity in this cancer. SWOG 1922 explores the clinical activity of FOLFIRI and ramucirumab with paclitaxel in the second- and later-line setting for small bowel adenocarcinoma. Methods: This is a randomized phase II selection design clinical trial of FOLFIRI (5-fluorouracil, leucovorin and irinotecan) every two weeks or ramucirumab D1,15 and paclitaxel D1,8,15 every 4 weeks with the primary endpoint of progression-free survival (PFS). Secondary endpoints include response rate, overall survival, and safety. Archived paraffin tumor tissue collection and serial blood collections are included for correlative analyses. Key eligibility include having mismatch repair proficient/microsatellite stable small bowel adenocarcinoma (ampullary location excluded); metastatic or locally advanced unresectable disease; prior fluoropyrimidine and/or oxaliplatin therapy; no prior treatment with irinotecan, ramucirumab, or taxanes; no recent bleeding, blood clots, or bowel perforation/fistula; and Zubrod performance status of 0/1. Measurable disease is not required. The null hypothesis is median PFS of 2.5 months. If a median PFS of at least 3.5 months is observed in one or both arms, the goal is to choose the better regimen with respect to this endpoint. The design provides a 90% probably of selecting the more active arm, assuming a hazard ratio of 1.4, if both arms meet this threshold. This trial is open and, as of September 1, 2021, 17 of 94 planned patients have been enrolled. NCT04205968. Funding: NIH/NCI/NCTN grants U10CA180888, U10CA180819, U10CA180820, U10CA180821, U10CA180868; and in part by Eli Lilly and Company. Clinical trial information: NCT04205968.
JAMA Cardiology
Authors: Phil Fontanarosa, Annette Flanagin, Brenda Deputy, Tracy Frey, Iris Lo, Kevin Brown, Rebecca Langley, Suzanne Newman, Connie Manno Senior, Sara Billings, Doug Brandt, Timothy Gray, Peter Olson, Juliet Orellana, Paul Ruich, Kirby Snell, Judith Copyreaders, Stephanie Ahlers, Jane Beckmeyer, Jan Calayag, Mary Clavey, Heather Coerver-Connolly, Bernadette Flint, Ruth Hromin, Laura Kaufman, Julia King, Martha Kurtz, Jenny Lentz, Tanya Mackay, Charon Martin, Lori Pierson, Thressa Ryan, Annette Smith, Donna Theuring, Christine Thordsen, Cara Tilles, Caroline Wallace, Editorial Woods, Wanda Assistant, Larry Bryant, Jacob Kendall-Taylor, Monica Managers, Fanny Staff, Anna Brown, Lee Bukowski, Lenette Calibeo, Tosca Gardner-Gullens, Erin Hall, Rachell Kato, Kenneth Lozano, Caroline Otani, Angelia Sietmann, Michael Berkwits, Eric Butkus, Jesse Mcquarters, Elena Guobyte, Emily Ling, Daniel Morrow, Shelly Steff, Social Media, Eman Hassaballa, Reuben Rios, Mary Ferkaluk, Jonathan Laxamana, Karen Bucher, Andy Rekito, Nick Reback, Lohitha Kethu, David Song, Thomas Cole, Marla Jeff, Deanna Willis, Yolanda Davis, Joseph Thornton, Deanna Bellandi, Jim Periodical, Thomas Easley, Brian Shields, Karen Adams-Taylor, Paul Gee, Monica Degroot, Euwanaha Joiner-Smith, Joshua Lane, Cindy Rendlen, Ellen Yoshihara, Annissa Zak, Julie Burton, Ronna Hewitt, Mary Sieck, Geneine Someren, Jamaal Vargas, Content Systems, Mike Bujewski, Nathan Mitre, Digital Production, Regina Brownlee, Amanda Camino, Brenda Chandler-Grayer, Emily Dunn, Amy Evers, Maleeka Holden, Teri Hutchison, Dan Knowles, Joshua Lampinen, Natalie Marsh, Patricia Panek, Marla Seidell, La Son, Diggs Sledge, Julian Graphics, Joe Amft, James Collver, Maria Duda, Fred Furtner, Carolyn Hall, Maria Kowalkowski, Joy Farrell, Maria Giannini, Sasha Grossman, Judith Literskis, Teresa Omiotek, Michael Ryder, James Madara, Howard Bauchner, Robert Bonow, Patrick O'gara, Marc Sabatine, Clyde Boston, Michael Pencina, Carolina North, Adrian Hernandez, Mhs Durham, North Carolina, Mark Huff Man, Ajay Kirtane, New York, Roxana Mehran, Pradeep Natarajan, Ann Boston, Carolina Sanjiv, J Shah, Mintu Turakhia, Sadiya Khan, Gregg Fonarow, Los Angeles, Elizabeth Mcnally, Laine Thomas, Akhil Narang, Heather Hsu, Andrew Boston, Ann Ibrahim, Julia Getts, Eugene Braunwald, Robert Califf, Judith Hochman, Donald Lloyd-Jones, Scm Chicago, Michael Parmacek, Daniel Simon, Sidney Smith, Chapel Hill, Carolina Douglas, E Vaughan, Myron Weisfeldt, Maryland Douglas, P Zipes, Paul Armstrong, Shinya Goto, Peter Liu, Renato Lopes, Carolina Maseri, Dorairaj Prabhakaran, Hugh Watkins, Harvey White, Habib Yacoub
Journal: JAMA Cardiology (2021)
Government Services
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
News in brief
Authors: Jack Williamson
Journal: The Lancet Healthy Longevity (2021)

The clinical value of convalescent plasma for treating patients with COVID-19 has been a key question of concern. Previously tested on patients who were moderately or severely ill with the disease, convalescent plasma provided only weak evidence of clinical efficacy. Another strategy, suggested by the Emergency Use Authorization, is to use high-titer convalescent plasma in patients shortly after onset of symptoms. In a multicentre, randomised controlled trial, Romina Libster (Fundación Infant, Buenos Aires, Argentina) and colleagues investigated 250 ml of convalescent plasma (with IgG titer >1:1000 against severe acute respiratory syndrome coronavirus 2 spike protein) versus placebo in 160 patients (mean age 77 years, including patients with coexisting conditions) within 72 h after the onset of mild COVID-19 symptoms.
Abstract 265: Impact of Changes in the Telephone Cardiopulmonary Resuscitation Instruction After Out-of-Hospital Cardiac Arrest
Authors: Ken Nagao, Hiroyuki Hanada, Yoshio Tahara, Hiroshi Nonogi, Naohiro Yonemoto, David F Gaieski, Noritoshi Ito, Hitoshi Hirose, Tsukasa Yagi, Nobutaka Chiba, Eizo Tachibana, Keijiro Saku, Hiroaki Simokawa
Journal: Circulation (2018)

Background: The international consensus on cardiopulmonary resuscitation (CPR) and emergency cardiovascular care science with treatment recommendations (CoSTR) 2010 changed the dispatcher-initiated telephone CPR instruction. Major changes of the telephone CPR instruction were simplified algorithm, elimination of “Look, listen, and feel for breathing” chest compressions first (C-A-B), chest compression only CPR if bystander was not trained in CPR, et al. However, few studies have investigated the efficacy of telephone CPR instruction based on the CoSTR 2010. Methods: From the All-Japan Utstein Registry for out-of-hospital cardiac arrest (OHCA) between 2006 and 2015, we enrolled adult (18 years or older) patients with bystander-witnessed OHCA and stratified by the two CoSTR eras (the CoSTR 2010 group from 2011 through 2015 versus the CoSTR 2005 group from 2006 through 2010). The primary endpoint was 30-day favorable neurological outcome after OHCA. Results: Of the 378,757 adult patients with bystander-witnessed OHCA, 199,117 (52.5%) received CPR based on the CoSTR 2010 and 179,640 (47.4%) received CPR based on the CoSTR 2005. In the whole cohort, the CoSTR 2010 group had higher proportion of cases receiving telephone CPR instruction than the CoSTR 2005 group (48.8% versus 40.9%, P&lt;0.001). In the subgroups of patients receiving telephone CPR instruction, the CoSTR 2010 group had higher proportion of bystander chest compression-only CPR (60.5% versus 47.3%, p&lt;0.001) and public access defibrillation (1.9% versus 0.9%, P&lt;0.001) than the CoSTR 2005 group. Although those subgroups had similar proportion of initial shockable cardiac arrest rhythm (15.2 % in the CoSTR 2010 group versus 15.3 % in the CoSTR 2005 group, P=0.63), the CoSTR 2010 group had higher frequency of the favorable neurological outcome than the CoSTR 2005 group (4.5 % versus 3.7%%, P&lt;0.001). In the subgroup of patients receiving telephone CPR instruction, an adjusted odds ratio for the favorable neurological outcome in the CoSTR 2010 group (reference, the CoSTR 2005 group) was 1.47 (95 % CI, 1.43-1.51, p&lt;0.001). Conclusions: Telephone CPR instruction based on the CoSTR 2010 was the preferable approach to resuscitation for adult patients with bystander-witnessed OHCA.
Pharmacology
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Exceptional matters
Authors: Keith Peters
Journal: The Lancet (2004)

Medical researchers in universities, research institutes and industry today are struggling to promote translational research—the catchphrase is from bench to bedside. The achievements of basic biomedical research and its potential in the postgenomic era are evident, but this Oration is in praise of clinical research. Archibald Garrod, the pioneer of clinical research of the past century, was greatly influenced by the Cambridge biologist and apostle of mendelism, William Bateson, whom I quote:
THE PROBLEM OF POPULATION.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Diagnosing atopic dermatitis in the first year of life
Journal: British Journal of Dermatology (2022)

Abstract Linked Article: Endre et al. Br J Dermatol 2022; 186:50–58. Atopic dermatitis is a common skin disease, often starting in the first year of life. However, the disease may be difficult to diagnose during infancy, even when using well-defined diagnostic criteria. Atopic dermatitis is also known as atopic eczema. The two terms are often used interchangeably in daily clinical practice, although eczema used alone is usually considered to be a more general term. In children, a diagnosis of atopic dermatitis is thought to mean a worse outcome compared with a diagnosis of eczema. In this study, we report the occurrence of eczema in over 1800 infants in Norway and Sweden at 3, 6 and 12 months of age, and how many of these would fulfil two widely used diagnostic criteria for atopic dermatitis called the UK Working Party criteria and the Hanifin &amp; Rajka’s criteria. Approximately one-third of all the infants had eczema at some point. However, only about one-third of these infants fulfilled either of the two sets of diagnostic criteria for atopic dermatitis. Those who already had eczema at 3 months and those with eczema at more than one visit were most likely to fulfil the criteria. More infants were diagnosed with atopic dermatitis by the Hanifin &amp; Rajka’s criteria than the UK Working Party criteria at 12 months. We found that a diagnosis of atopic dermatitis is hard to confirm in infancy. We recommend repeated examinations and using both sets of diagnostic criteria when diagnosing atopic dermatitis in infants. This approach may be relevant for research studies, but not so much in a busy clinical practice. The term infantile eczema may be more appropriate to use until the characteristics of atopic dermatitis have become clearer after infancy. Linked Article: Endre et al. Br J Dermatol 2022; 186:50–58.
Atriventricular nodal block in acute myocardial infarction treated with thrombolytic therapy is common and protends poor prognosis: Results from large trials of thrombolytic therapy Sana M. Al-Khatib, E. Magnus Ohman, Harvey D. White, Christopher B. Granger, Robert M. Califf, Rakhi Kilaru, Eric J. Topol. Duke Clinical Research Institute, Durham, NC
Journal: Journal of the American College of Cardiology (2001)
Correction
Journal: BMJ (1949)

suggests equal pay for officers of the Colonial Medical Service, whether patriate or expatriate.This I agree with, provided the salaries are in relation to the economics of the Colony concerned.Present basic salaries in most cases are as much as the individual Colonies will be able to afford when health and welfare services are fully developed.However, no European medical officers cou'd be recruited on the basic salary alone, and would require their salaries to be made up by expatriation allowances.But these allowances should be paid by the Colonial Office from United Kingdom funds under the Colonial Development and Welfare Acts, and have nothing to do with the finances of the individual Colonies.This would avoid locally recruited officers complaining that Europeans are paid more by the Colonies than they are, and might help to unify the Colonial Medical Sorvice.Incidentally, how many locally recruited medical officers belong to the Colonial Medical Service ?Most of them, I believe, are not liable to transfer outside the Colony in which they have been recruited, and therefore are not part of the unified service.-Iam, etc.. P. Q.
The dihydropyridine Ca channel blocker, nifedipine, limits infarct size via bradykinin- and NO-dependent mechanisms in dogs Masafumi Kitakaze, Yoshiro Shinozaki, Hidezi Mori, Hiroshi Asanuma, Shoji Sanada, Masanori Asakura, Hisakazu Ogita, Yulin Liao, Koichi Node, Seiji Takashima, Tsunehiko Kuzuya, Masatsugu Hori. Osaka University Graduate School of Medicine, Osaka, Japan
Journal: Journal of the American College of Cardiology (2001)
Cerebral blood flow can be accurately measured using contrast enhanced ultrasound imaging Se-Joong Rim, Howard Leong-Poi, Jian-Ping Bin, Jonathan R. Lindner, Daniel Couture, Dilantha Ellegala, Holland Mason, Marcel Durieux, Sanjiv Kaul. University of Virginia, Charlottesville, VA
Journal: Journal of the American College of Cardiology (2001)
NONINVASIVE RENAL SYMPATHETIC DENERVATION BY TRANSABDOMINAL HIGH INTENSITY FOCUSED ULTRASOUND IN A PRECLINICAL CANINE MODEL
Authors: Jing Huang, Qifeng Wang, Rui Guo, Shunkang Rong, Gang Yang, Qque Zhu, Jiang Yonghong, Changming Deng, Dichuan Liu, Qi Zhou, Qi Wu, Shunhe Wang, Qi Wang, Han Lei, Tong–chuan He
Journal: Journal of the American College of Cardiology (2013)